false 0001716947 0001716947 2023-12-29 2023-12-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 29, 2023 (December 29, 2023)

 

 

 

Ensysce Biosciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38306   82-2755287

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

 

7946 Ivanhoe Avenue, Suite 201

La Jolla, California

   92037
(Address of principal executive offices)   (Zip Code)

 

(858) 263-4196

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ENSC   The Nasdaq Stock Market LLC

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 8.01 Other Events.

 

As previously reported, on December 19, 2023, Ensysce Biosciences, Inc. (the “Company”) postponed until December 29, 2023, the December 20, 2023, Special Meeting of Stockholders due to the lack of a quorum. The lack of a quorum on December 29, 2023, resulted in no meeting on that date. As a result, no matters were submitted to a vote of security holders on December 29, 2023 and no information is required to be reported under Item 5.07 of a Current Report on Form 8-K.

 

As previously reported, the Company entered into a Securities Purchase Agreement as of October 23, 2023 (the “Agreement”). Because the Company did not obtain stockholder approval on December 29, 2023, of certain matters that were to have been considered at that meeting, it is required to call a meeting every four months until the earlier of the date such stockholder approval is obtained or the notes issued under the Agreement are no longer outstanding.

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: December 29, 2023 Ensysce Biosciences, Inc.
     
  By: /s/ Lynn Kirkpatrick
  Name Dr. Lynn Kirkpatrick
  Title: President and Chief Executive Officer
    (Principal Executive Officer)

 

 

 

 

v3.23.4
Cover
Dec. 29, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 29, 2023
Entity File Number 001-38306
Entity Registrant Name Ensysce Biosciences, Inc.
Entity Central Index Key 0001716947
Entity Tax Identification Number 82-2755287
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 7946 Ivanhoe Avenue
Entity Address, Address Line Two Suite 201
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code (858)
Local Phone Number 263-4196
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ENSC
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Ensysce Biosciences (NASDAQ:ENSC)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Ensysce Biosciences Charts.
Ensysce Biosciences (NASDAQ:ENSC)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Ensysce Biosciences Charts.